RESUMEN
BACKGROUND: The use of mucoadhesive natural polymers in designing mucoadhesive patch systems has received much attention. OBJECTIVES: The study involved the development and evaluation of buccal patches of atenolol using fenugreek (Trigonella foenum-graecum L.) seed mucilage with hydroxylpropyl methyl cellulose (HPMC K4M) and a backing membrane (ethyl cellulose 5% w/v). MATERIAL AND METHODS: These atenolol-releasing buccal patches were prepared using a solvent casting technique. The buccal patches prepared were evaluated for average weight, thickness, drug content, folding endurance and moisture content. Ex vivo mucoadhesive strength, force of adhesion and bonding strength were determined using porcine buccal mucosa. The mucosal permeation of atenolol through the porcine buccal mucosa was carried out using a Franz diffusion cell in phosphate buffer saline, pH 6.8. These buccal patches were also characterized by SEM and FTIR spectroscopy. RESULTS: The average weight, thickness, drug content, folding endurance and moisture content of these atenolol-releasing buccal patches were found satisfactory for all the patches. Amongst all, the F-4 buccal patch showed maximum mucoadhesive strength (31.12 ±1.86 g), force of adhesion (30.53 × 10-2 N) and bond strength (1748.89 N/m2). Ex vivo atenolol permeation from the buccal patches showed drug permeation across the excised porcine buccal mucosa over 12 h. The F-4 buccal patch showed maximum permeation flux (29.12 µg/cm2/h). CONCLUSIONS: The developed atenolol-releasing buccal patches can be beneficial over the conventional drug delivery systems to decrease the dosing frequency and enhance patient compliance.
Asunto(s)
Atenolol/administración & dosificación , Sistemas de Liberación de Medicamentos , Mucosa Bucal/metabolismo , Extractos Vegetales/química , Polisacáridos , Trigonella/química , Animales , Atenolol/farmacocinética , Cabras/metabolismo , Permeabilidad , Porcinos/metabolismoRESUMEN
The authors evaluated the contribution of the SLCO2B1 polymorphism to the pharmacokinetics of celiprolol at a microdose (MD) and therapeutic dose (TD) and compared pharmacokinetic proportionality between the 2 dose forms in 30 SLCO2B1 genotype-matched healthy volunteers. Three drugs (celiprolol, fexofenadine, and atenolol) were orally administered as a cassette dosing following the MD (totally 97.5 µg) and then a TD (100 mg) of celiprolol, with and without grapefruit juice. The mean AUC(0-24) of celiprolol was lower in SLCO2B1*3/*3 individuals (775 ng·h/mL) than in *1/*3 (1097 ng·h/mL) and *1/*1 (1547 ng·h/mL) individuals following the TD, and this was confirmed in population pharmacokinetic analysis with statistical significances; however, SLCO2B1 genotype-dependent differences disappeared following the MD. Dose-normalized AUC of celiprolol at the MD was much lower than that at the TD, explained by the saturation of the efflux transporter. Thus, the effect of SLCO2B1 polymorphism on the AUC of celiprolol clearly observed only at the TD may be due to the saturation of the efflux transport systems.
Asunto(s)
Antagonistas de Receptores Adrenérgicos beta 1/farmacocinética , Celiprolol/farmacocinética , Interacciones Alimento-Droga , Transportadores de Anión Orgánico/genética , Administración Oral , Antagonistas de Receptores Adrenérgicos beta 1/administración & dosificación , Adulto , Área Bajo la Curva , Atenolol/administración & dosificación , Atenolol/farmacocinética , Bebidas , Celiprolol/administración & dosificación , Citrus paradisi/química , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Farmacogenética , Polimorfismo Genético , Terfenadina/administración & dosificación , Terfenadina/análogos & derivados , Terfenadina/farmacocinética , Adulto JovenRESUMEN
The intestinal permeability and transport of 10 neolignans isolated from MYRISTICA FRAGRANS were studied by using the Caco-2 cell monolayer model. The 10 neolignans were measured by HPLC. Transport parameters and permeability coefficients were then calculated and compared with those of the model compounds, propranolol and atenolol. Among the 10 neolignans, the 8- O-4'-type neolignans demonstrated high permeability while the benzofuran-type neolignans were of poor to moderate permeability. Among them, eight neolignans were transported mainly VIA passive diffusion. These findings indicate that the 8- O-4'-type neolignans are well-absorbed compounds and can be used as oral leading compounds in drug discovery.
Asunto(s)
Absorción Intestinal , Mucosa Intestinal/metabolismo , Lignanos/farmacocinética , Myristica/química , Semillas/química , Atenolol/química , Atenolol/farmacocinética , Transporte Biológico , Células CACO-2 , Cromatografía Líquida de Alta Presión , Difusión , Humanos , Lignanos/química , Lignanos/aislamiento & purificación , Permeabilidad , Propranolol/química , Propranolol/farmacocinéticaRESUMEN
HO-1-u-1 (Ueda-1) is a human tumor cell line established from human sublingual squamous cell carcinoma. In previous study, HO-1-u-1 cell line was grown on cell culture inserts and utilized as in vitro model for screening sublingual drug delivery. The aim of current study was to further investigate the effects of pH, osmolarity and permeation enhancer, sodium glycodeoxycholate (GDC) on the permeability of three beta-blockers with different lipophilicities. The cytotoxicity was evaluated by MTS/PES assay. The permeability studies were carried out using the cell culture model and compared with that obtained from fresh porcine sublingual mucosa. The results showed the enhancement effects caused by pH, osmolarity and GDC were highly lipophilicity-dependent and in the order atenolol>metoprolol>propranolol. The apparent permeability coefficients (P(app)) of all the three beta-blockers were significantly increased by increasing pH. However, less enhancing effects were observed by non-physiological osmolarity or the presence of GDC in permeability study using both cell culture and porcine sublingual mucosa. The present results suggested that the HO-1-u-1 cell culture model maybe a useful and effective in vitro model for evaluating the enhancement effects and mechanism in sublingual drug delivery.
Asunto(s)
Adyuvantes Farmacéuticos/química , Antagonistas Adrenérgicos beta/farmacocinética , Ácido Glicodesoxicólico/química , Modelos Biológicos , Mucosa Bucal/metabolismo , Administración Sublingual , Animales , Atenolol/farmacocinética , Transporte Biológico , Línea Celular Tumoral , Cromatografía Líquida de Alta Presión , Difusión , Evaluación Preclínica de Medicamentos/métodos , Humanos , Concentración de Iones de Hidrógeno , Técnicas In Vitro , Masculino , Metoprolol/farmacocinética , Concentración Osmolar , Permeabilidad , Propranolol/farmacocinética , Sus scrofaRESUMEN
A polymer matrix system for transdermal delivery of Atenolol was developed for its prolonged and controlled release systemic availability. To achieve the desired and controlled release rate, different combinations of Eudragit RL with polyvinyl pyrrolidone and polyethylene glycol 4000 were used in the preparations of polymeric matrix system. These preparations were evaluated for in vitro release and permeation of the drug across pig skin. The desired systems exhibited linear relationship between drug release (Q) versus ne0.8(hr0.8). The product exhibiting required skin permeation 64 mcg/h/cm2 to achieve an effective plasma concentration was selected for the in vivo performance evaluation. The drug plasma profile was compared with the plasma profile obtained following the administration of a conventional oral dose of Atenolol. The study revealed that the designed polymeric matrix transdermal drug delivery system of Atenolol could be successful with improved performance.
Asunto(s)
Atenolol/farmacocinética , Sistemas de Liberación de Medicamentos/métodos , Tecnología Farmacéutica/métodos , Administración Cutánea , Administración Oral , Antagonistas Adrenérgicos beta/administración & dosificación , Antagonistas Adrenérgicos beta/farmacocinética , Animales , Área Bajo la Curva , Atenolol/administración & dosificación , Atenolol/sangre , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Evaluación Preclínica de Medicamentos/métodos , Femenino , Masculino , Polietilenglicoles/química , Polímeros/química , Povidona/análogos & derivados , Povidona/química , Conejos , Piel/metabolismo , Absorción Cutánea , Porcinos , Resistencia a la Tracción , Factores de TiempoRESUMEN
This study was conducted mainly to investigate the relative contributions of various mechanisms by which bile salts and EDTA may improve the in vitro rectal penetration of insulin in the albino rabbit. Insulin could not cross the rectal mucosa unless Na glycocholate or other penetration enhancers were present. Penetration enhancement was attributed primarily to Na glycocholate's ability to reduce the barrier function of the rectal membrane and to increase the fraction of insulin in its monomeric form, and secondarily to Na glycocholate's ability to protect insulin from proteolysis. Na glycocholate was more effective than Na taurocholate, but less effective than Na deoxycholate and polyoxyethylene-9-lauryl ether in enhancing rectal insulin penetration. Although EDTA at 0.01 and 0.1% did not affect rectal insulin penetration, it augmented the penetration enhancement effect of 1% Na glycocholate without causing additional damage to the rectal membrane, as judged by protein release. Such an action was attributed to the synergistic effect associated with: 1) an increase in the permeability of the paracellular pathway by EDTA and 2) an increase in the proportion of insulin in the monomeric form by Na glycocholate. Results from parallel in vivo experiments have indicated that it may be possible to achieve significant penetration enhancement by using a combination of otherwise membrane-damaging penetration enhancers which act by complementary mechanisms at concentrations that are both effective and well tolerated by mucosal epithelial cells.
Asunto(s)
Ácidos y Sales Biliares/farmacología , Permeabilidad de la Membrana Celular/efectos de los fármacos , Insulina/farmacocinética , Recto/efectos de los fármacos , Animales , Atenolol/farmacocinética , Ácido Edético/farmacología , Masculino , Conejos , Recto/metabolismo , Timolol/farmacocinéticaRESUMEN
1. Ten healthy subjects received two treatments: a single 1 g oral dose of nalidixic acid (NA) followed 1 h later by either an infinitesimal dilution of the drug (NA 7CH) or by succussed water which served as placebo. The study was repeated 18 months later in 10 different subjects. 2. A further 10 healthy subjects received three treatments: a single 100 mg oral dose of atenolol (AT) followed 3 h later by either placebo or a dilution of AT (AT 7CH) or of bisoprolol (BI 7CH). The homoeopathic preparations were administered by the sublingual route. 3. In the first NA experiment NA 7CH significantly shortened the elimination half-life of NA from 8.6 +/- 2.2 (placebo) to 6.4 +/- 1.6 h (NA 7CH). In the second NA experiment none of the pharmacokinetic parameters was modified significantly by the administration of NA 7CH. Neither AT 7CH nor BI 7CH modified the pharmacokinetics of AT.